StockJungle
Latest
$CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June. $CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June.
Editorial product

Stock Picks of the Week

A weekly stock pick column is the easiest place on a finance site to slip into hype. The original StockJungle did the opposite. Picks of the week were structured, attributed, and tracked, which made the segment useful instead of noisy.

Updated April 21, 2026 · StockJungle archive

What this segment was

A short list of names selected each week from the broader research stream. The point was not to predict the next week's price action. It was to teach a reader to evaluate ideas across different investing styles by reading several short, signed pieces side by side.

How picks were selected

Picks were drawn from current published research, not invented for the column. Each pick had a name behind it, a thesis, an entry price, and an obvious benchmark. The editorial team did not try to balance the picks to look diversified. Some weeks the list leaned toward value names, some weeks toward growth, and some weeks toward an unusual special situation. The week's picks reflected what the analysts were actually working on, not what looked tidy.

Tracking and accountability

Every pick was time stamped at the time of publication. Subsequent performance was attached to the contributor's record. There was no editorial cleanup of bad picks. A pick that aged poorly stayed on the contributor's page. The accountability was the discipline that kept the column honest.

Why this kind of column needs care

A weekly pick page invites two failure modes. The first is hype, where the operator quietly promotes whichever name is moving and pretends it was a thoughtful selection. The second is amnesia, where bad picks vanish and good picks are remembered. The original StockJungle structure prevented both because the picks were drawn from real research and the record was public.

Connection to today's research

The current StockJungle does not publish a weekly picks column in the same shape. The closest equivalent is the rolling stream of research from the named Portfolio Managers, where each piece is signed, attributed, and tied to a tracked model portfolio. A reader who wants the spirit of the original column can browse the recent articles and read two or three by managers from different schools on the same week.

Related reading